| Symbol | PXXLF |
|---|---|
| Name | POXEL SA |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 69007 France Immeuble Le Sunway 259-261 Avenue Jean Jaures |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://www.poxelpharma.com/en_us/investors |
| Incorporation | FR |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Euronext Paris |
| CIK | — |
| Description | Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. Additional info from OTC: |
No news found.